EGFR and head and neck cancer: Similarly, treatment of head and neck cancer cell lines with OSI-027, an mTORC1/2 inhibitor, synergistically enhances the effect of the reversible EGFR tyrosine kinase inhibitor erlotinib on cell survival [24].